Henry Schein (HSIC) Stock Price, Fundamentals & Analysis

What HSIC does

Henry Schein (HSIC) is a US stock in the Healthcare sector, specifically the Medical Distribution industry, headquartered in Melville, United States. The company provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand.

Key numbers explained

• The current price is 85.05 USD, which is the latest trading price for one share of Henry Schein.
• The trailing P/E ratio of 24.2 divides the current share price by the last twelve months of earnings per share (3.52 USD), showing how much investors pay per dollar of recent earnings.
• The forward P/E ratio of 14.2 uses expected future earnings, offering a view of valuation based on what analysts anticipate.
• The dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company currently does not distribute cash dividends to shareholders.
• The beta of 0.81 suggests the stock has historically moved less than the overall market, with a value below 1 indicating lower volatility.
• The price-to-book ratio of 3.01 compares the market price to the company's book value per share, a common way to assess whether a stock trades at a premium to its net assets.
• The debt-to-equity ratio of 80.7% indicates that for every dollar of shareholder equity, the company has about 0.81 in debt, a measure of financial leverage.
• The return on equity of 8.9% shows how much profit the company generates for each dollar of shareholder equity.

Recent news

Recent headlines include questions about whether investors are undervaluing Henry Schein and what makes it a new buy stock, as well as a comparison of HSIC against SAUHY as a value stock. Other stories note that DermaSensor raised $5 million and opened a round to the public via Wefunder, alongside four major new US partnerships, and that Henry Schein will distribute Applied BioCode's MDx-3000 System in the US. Additional coverage mentions Henry Schein participating in an upcoming investor conference in September.

What to watch

Investors tracking Henry Schein often look at its position within the S&P 500 and its relationship to peers such as Agilent Technologies (A), Charles River Laboratories (CRL), Amgen (AMGN), Veeva Systems (VEEV), Becton Dickinson (BDX), IQVIA (IQV), and Solventum (SOLV). Key factors for this kind of medical distribution stock include changes in healthcare spending, reimbursement policies, product innovation, and competitive dynamics within the medical distribution industry. Broader market conditions, interest rates, and regulatory developments in the healthcare sector can also influence the stock's performance.